Literature DB >> 33446156

Thymic rebound hyperplasia post-chemotherapy mistaken as disease progression in a patient with lymphoma involving mediastinum: a case report and reflection.

Lei Qiu1, Yi Zhao2, Yang Yang2, He Huang2, Zhen Cai2, Jingsong He3.   

Abstract

BACKGROUND: Chemotherapy can cause thymic atrophy and reduce T-cell output in cancer patients. However, the thymus in young adult patients has regenerative potential after chemotherapy, manifesting as thymic hyperplasia which can be easily mistaken as residual disease or recurrence in patients suffering lymphoma. CASE
PRESENTATION: This study reports a case of lymphoma in a young female adult who was initially diagnosed with an anterior mediastinal mass, and was found to have soft tissue occupying the anterior mediastinum repeatedly after chemotherapy, suggesting a lymphoma residue or disease progression. From discussions by a multi-disciplinary team (MDT), the anterior mediastinal mass of the patient was considered unknown and might be thymus tissue or tumor tissue, and it was eventually identified as thymus tissue via histopathology.
CONCLUSIONS: The anterior mediastinal mass appearing after chemotherapy in patients with lymphoma can be considered as enlarged thymus, and such phenomenon is frequent in young adult patients who undergo chemotherapy or autologous hematopoietic stem cell transplantation. Additionally, detection of thymic output cells in peripheral blood might be a feasible approach to differentiate thymic hyperplasia from lymphoma.

Entities:  

Keywords:  Case report; Lymphoma; Misdiagnosis; Recent thymic emigrants; Thymic hyperplasia

Year:  2021        PMID: 33446156     DOI: 10.1186/s12893-021-01048-y

Source DB:  PubMed          Journal:  BMC Surg        ISSN: 1471-2482            Impact factor:   2.102


  1 in total

1.  Investigating Factors Associated with Thymic Regeneration after Chemotherapy in Patients with Lymphoma.

Authors:  Dao-Ping Sun; Li Wang; Chong-Yang Ding; Jin-Hua Liang; Hua-Yuan Zhu; Yu-Jie Wu; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  Front Immunol       Date:  2016-12-27       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.